Rare Disease Market Access: Why the New Access Playbook Is Emerging Here First
- Jul 27
- 5 min read
Updated: Jul 28
Want the downloadable brief? Get the full Signal 5 PDF and webinar replay resources from our Access Inflection resource page.
Rare disease has always required a different approach to market access.
Small patient populations, limited natural history data, evolving standards of care, and high treatment costs create uncertainty that traditional evidence packages do not always resolve.
But rare disease is no longer simply an exception to the broader market.
It is increasingly a leading indicator of how payer evidence expectations, stakeholder engagement, and access decision-making may evolve across therapeutic areas.
During eMAX Health Systems’ webinar, The Access Inflection: When the 2025 Playbook Stops Working, a live panel of senior payer and market access leaders discussed how plans are adapting when traditional sources do not provide enough information to make confident coverage decisions.
Their message was clear: manufacturers need to build a broader evidence and stakeholder strategy well before a product reaches the P&T agenda.
Rare Disease Decisions Require More Than a Product Dossier
Payers evaluating rare disease therapies are often working with limited clinical evidence, small study populations, single-arm trials, incomplete treatment guidelines, and little real-world experience.
That makes the surrounding disease context especially important.
Plans want to understand:
How patients are currently identified and managed
The natural history and burden of the disease
Current on-label and off-label treatment patterns
Healthcare resource utilization
Plan-level prevalence
The number of patients likely to be eligible for treatment
Where the product may fit within the treatment pathway
As one panelist explained:
“We want to know the patient journey. We want to know the disease burden. We want to know healthcare resource utilization for those patients.”
For manufacturers, disease education cannot stop at awareness or unmet need.
The evidence strategy needs to translate the disease into a payer-relevant decision framework: which patients are likely to qualify, what costs they generate today, how treatment may change those costs, and where uncertainty remains.
Not Every Advocacy Source Carries the Same Weight
Patient advocacy organizations, registries, foundations, and other third-party groups can help fill evidence gaps in rare disease.
But payers do not consider every source equally credible.
One webinar panelist described the distinction this way:
“There are advocacy groups with a capital A, and there are advocacy groups with a small A.”
The difference is scientific credibility.
Payers may place greater value on organizations that maintain robust registries, support high-quality research, develop evidence-based guidance, grade the strength of available evidence, and contribute meaningful disease-state data.
Organizations focused primarily on advocating for unrestricted access may still play an important role, but their recommendations may not carry the same weight in formulary decision-making.
This means manufacturers should evaluate advocacy engagement as part of the evidence strategy, not only as a relationship-building or awareness initiative.
The important question is not simply whether an advocacy organization is influential.
It is whether the organization’s evidence, methodology, registry infrastructure, and scientific reputation can withstand payer scrutiny.
Rare Disease Is Becoming a Treatment-Pathway Challenge
The phrase “rare disease” can suggest a category with few or no available options.
That is changing.
Many rare disease markets now include multiple treatments with different mechanisms of action, administration models, evidence profiles, and costs.
As one panelist observed:
“Rare is not as rare as it used to be. There is a lot of competition in the spaces today.”
As treatment options expand, payers are asking more complex questions.
Which therapy should be used first?
Should different mechanisms be sequenced?
Is combination therapy appropriate?
What happens when a patient progresses after gene therapy?
Can a patient transition from a gene therapy to chronic treatment, or vice versa?
Does evidence support switching between therapies?
These are no longer questions that can be answered by showing that a product works.
Manufacturers need evidence that explains where the product fits.
A therapy intended to become first line may need comparative evidence against the treatments it is expected to displace.
A product expected to serve as an add-on therapy may need clinical trial data demonstrating incremental value in combination.
A treatment positioned after progression or gene therapy may need evidence supporting outcomes in those specific patients.
The intended access position should shape the evidence plan from the beginning.
Early Payer Engagement Is Part of Evidence Readiness
Rare disease access strategy cannot be built solely through one-way communication.
Panelists emphasized the value of pre-approval information exchange that gives payers time to understand an emerging product, ask questions, challenge assumptions, and request additional evidence.
One payer described these discussions as particularly useful when they occur within approximately six months of a PDUFA date:
“It gives us some degree of awareness of the product, its potential positioning … being able to ask questions, request additional data, and just get familiarity with a new product well before it suddenly gets FDA approved and shows up on our P&T agenda.”
That distinction matters.
A webinar, dossier presentation, or standard product briefing may communicate information.
Interactive engagement helps manufacturers discover which uncertainties could affect access while there is still time to address them.
For rare disease teams, pre-approval engagement can help identify:
Unanswered disease-state questions
Concerns about the eligible population
Evidence gaps affecting treatment sequencing
Questions about real-world use
Budget-impact assumptions that require validation
Potential requirements for outcomes-based or risk-sharing agreements
Misalignment between intended positioning and payer expectations
Early engagement should function as a learning loop, not simply a launch communication milestone.
What Rare Disease Market Access Means for Manufacturers
Rare disease exposes weaknesses in the traditional market access playbook earlier than many other therapeutic areas.
A strong clinical profile may still leave payers uncertain about the patient population, disease burden, comparator, treatment sequence, real-world outcomes, or financial risk.
Manufacturers preparing for launch should ask:
Have we mapped the natural history and current patient journey?
Can we quantify plan-level prevalence, eligibility, resource use, and budget exposure?
Have we evaluated the scientific credibility of advocacy groups, registries, and foundations?
Does our evidence plan address sequencing, switching, combination use, and progression?
Are clinical development and HEOR aligned with the intended access position?
Do payers have an opportunity to challenge our assumptions before approval?
The goal is not simply to build a larger evidence package.
It is to build the evidence and stakeholder ecosystem required to reduce uncertainty.
Start With the Endgame and Work Backward
One panelist summarized the strategic imperative:
“You really have to think about where your product is going to be positioned as you are launching … think about the endgame first and work backwards into what you actually want to invest in.”
That principle extends beyond rare disease.
As payer decision-making becomes more evidence-intensive, interactive, and pathway-focused, manufacturers across therapeutic areas may need to connect clinical development, HEOR, advocacy, pricing, and stakeholder engagement earlier.
Rare disease is where that next access model is already becoming visible.
How MAVA® Supports Rare Disease Access Planning
MAVA® gives pharmaceutical and biotech teams rapid, confidential access to curated payer and healthcare decision-maker panels.
Teams can use MAVA to explore how stakeholders may evaluate:
Disease burden and natural history
Patient population and eligibility assumptions
Advocacy and registry credibility
Clinical and real-world evidence gaps
Treatment sequencing and combination use
Intended product positioning
Budget impact and contracting uncertainty
Pre-approval communication strategy
Instead of waiting for questions to surface during formulary review, manufacturers can pressure-test assumptions while evidence and strategy can still be refined.
The Takeaway
Rare disease is not only where access is difficult.
It is where the future market access operating model is emerging first.
Payers are combining clinical evidence with disease-state intelligence, registries, advocacy resources, real-world data, provider perspectives, and direct manufacturer engagement to build a more complete decision context.
Manufacturers that establish credible evidence sources, define the intended treatment position, quantify the payer-relevant disease burden, and engage stakeholders early will be better positioned to reduce uncertainty and support appropriate access.
The next access playbook begins before approval.
It begins by defining the endgame and building backward from the decision payers will ultimately need to make.
